Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
32,500
Stocks News & Analysis
stocks
5 star fully franked ASX dividend payer
Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,886.60 | 35.90 | 0.41% |
| CAC 40 | 8,082.60 | 4.12 | 0.05% |
| DAX 40 | 25,435.20 | 60.78 | 0.24% |
| Dow JONES (US) | 51,481.51 | 347.11 | -0.67% |
| FTSE 100 | 10,704.77 | 19.89 | 0.19% |
| HKSE | 24,523.57 | 118.94 | -0.48% |
| NASDAQ | 26,820.38 | 248.34 | -0.92% |
| Nikkei 225 | 65,481.27 | 396.35 | -0.60% |
| NZX 50 Index | 13,683.63 | 147.05 | -1.06% |
| S&P 500 | 7,683.69 | 59.72 | -0.77% |
| S&P/ASX 200 | 8,709.30 | 29.60 | 0.34% |
| SSE Composite Index | 3,830.45 | 6.83 | 0.18% |